Treatment options for MDR- and XDR-TB

Kwok Chiu Chang, Giovanni Sotgiu

Source: Eur Respir Monogr 2017; 75: 232-244

Journal Issue: Anti-infectives and the Lung

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Kwok Chiu Chang, Giovanni Sotgiu. Treatment options for MDR- and XDR-TB. Eur Respir Monogr 2017; 75: 232-244

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47: 1235-1243 Year: 2016
Treatment of MDR-TB Source: International Congress 2015 – CC1 Diagnosis and management of MDR-TB Year: 2015
Who is responsible for MDR- TB? Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Efficiency of Bedaquiline in treatment of XDR-TB Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017
Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB Source: ERJ Open Res, 5 (2) 00046-2019; 10.1183/23120541.00046-2019 Year: 2019
Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009
MDR- and XDR-TB in Germany Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009
Linezolide in complex treatment of XDR-TB patients Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017
Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017
Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47:1758-1766 Year: 2016
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Treatment of drug-susceptible and drug-resistant tuberculosis Source: Eur Respir Monogr 2018; 82: 152-178 Year: 2018
Diagnosis of MDR-TB Source: International Congress 2015 – CC1 Diagnosis and management of MDR-TB Year: 2015